Close Menu

Sophia Genetics

The partnership aims to improve cancer molecular profiling by combining Horizon's HDx reference standards with Sophia's artificial intelligence solution.

The companies will combine their respective technologies to provide an integrated analytical and next-generation sequencing sample preparation offering for cancer research.

The co-marketing arrangement will initially cover hospitals and laboratories in Europe, the Middle East, and Africa.

Sophia's platform will be used to analyze data from Devyser's hereditary breast cancer and cystic fibrosis testing kits.

Internal benchmarks from the company show that the new technology, to be released next month, predicts variant pathogenicity with 98 percent accuracy.

The firms plan to combine Sophia's DDM software with Multiplicom's molecular diagnostic kits, and sell the solution to European hospitals and laboratories.

The partners will work on alternatives to current data protection methods which they say make healthcare data unusable for analysis, diagnostics.

The partnership will pair Sophia's informatics infrastructure with IDT's panel to provide an NGS-based solution for routine clinical diagnostics.

The companies are combining their respective products to provide a solution that covers genetic testing from sample prep to clinical reports.

The round was led by Belgian billionaire and founder of Omega Pharma Marc Coucke.

Pages

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

In Science this week: whole-genome sequencing of single sperm cells, and more.